Sun Pharmaceutical Industries' Q1 FY 2025-26 Quarter Results

Result Summary

• Sun Pharmaceutical Industries Ltd reported a 13.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.6%.
• Its expenses for the quarter were up by 6.8% QoQ and 5.8% YoY.
• The net profit decreased 13.8% QoQ and decreased 19.8% YoY.
• The earnings per share (EPS) of Sun Pharmaceutical Industries Ltd stood at 9.5 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sun Pharmaceutical Industries Ltd is a leading pharmaceutical company based in India. It is renowned for its diverse portfolio of pharmaceutical products, which includes generics, branded generics, over-the-counter (OTC) products, specialty drugs, and active pharmaceutical ingredients (APIs). The company primarily operates in the pharmaceutical industry, which is characterized by research and development, manufacturing, and distribution of medication. Sun Pharma has a significant global presence, with operations in multiple countries across the globe. The company is known for its commitment to innovation, quality, and customer satisfaction. Recent developments or specific strategic initiatives by Sun Pharma are not available in the current dataset.

Revenue

In Q1FY26, Sun Pharmaceutical Industries Ltd reported a total income of ₹14,315.86 crores, reflecting a quarter-over-quarter (QoQ) increase of 13.7% from ₹12,588.84 crores in Q4FY25. Compared to the same quarter in the previous financial year (Q1FY25), the total income grew by 8.6% from ₹13,185.30 crores. This upward trend in revenue indicates a positive trajectory in the company's income generation over both the quarterly and annual periods. The increase in revenue could be attributed to various factors, including potential increases in sales volume, pricing adjustments, or expansion into new markets or product lines. However, specific details regarding the drivers of revenue growth are not provided.

Profitability

The company's profitability metrics show a mixed performance. In Q1FY26, Sun Pharma's Profit Before Tax (PBT) was ₹3,172.77 crores, marking a QoQ increase of 12.7% from ₹2,815.52 crores in Q4FY25. However, there is a year-over-year (YoY) decrease of 7.3% from ₹3,423.50 crores in Q1FY25. The tax expenses for Q1FY26 were significantly higher at ₹870.15 crores, representing a substantial QoQ increase of 484.3% from ₹148.93 crores in Q4FY25 and a 57.6% increase YoY from ₹552.25 crores in Q1FY25. Consequently, the Profit After Tax (PAT) declined to ₹2,292.87 crores in Q1FY26, a decrease of 13.8% QoQ from ₹2,658.74 crores in Q4FY25 and a 19.8% drop YoY from ₹2,860.51 crores in Q1FY25. Earnings per Share (EPS) also decreased to ₹9.50 in Q1FY26, down from ₹11.10 in Q4FY25 and ₹11.80 in Q1FY25, reflecting a decline of 14.4% QoQ and 19.5% YoY.

Operating Metrics

Analyzing the operating expenses, Sun Pharma's total expenses for Q1FY26 amounted to ₹10,325.09 crores, which is a 6.8% increase QoQ from ₹9,671.68 crores in Q4FY25 and a 5.8% increase YoY from ₹9,761.80 crores in Q1FY25. This increase in expenses could be indicative of higher operational costs, increased production volumes, or investment in research and development activities. The data indicates an increase in tax expenses, which has affected the net profitability despite the rise in total income. The company’s operating performance over the quarter shows a positive income trajectory, though offset by increased tax liabilities and operational expenses, impacting the net profits and earnings per share.